The combination of anti-PD1 and a mouse analog of PYX-201, an antibody-drug conjugate targeting the extra-domain B splice variant of fibronectin (EDB+FN), shows greater anti-tumor efficacy than either treatment alone – Abstract Number: 3137 By Dan The combination of anti-PD1 and a mouse analog of PYX-201, an antibody-drug conjugate targeting the extra-domain B splice variant of fibronectin (EDB+FN), shows greater anti-tumor efficacy than either treatment alone – Abstract Number: 3137 Read More »
Evaluation of PYX-201, an EDB+FN-targeting ADC, in a comprehensive PDX mini-trial study enables identification of gene signatures associated with anti-tumor activity – Abstract Number: 3120 By Dan Evaluation of PYX-201, an EDB+FN-targeting ADC, in a comprehensive PDX mini-trial study enables identification of gene signatures associated with anti-tumor activity – Abstract Number: 3120 Read More »
Sarcomas express extra domain B of fibronectin and preclinical patient-derived xenograft models of several sarcoma subtypes are sensitive to the stroma targeting antibody drug conjugate PYX-201 – Abstract #: 1854935 By lsc-webmaster Sarcomas express extra domain B of fibronectin and preclinical patient-derived xenograft models of several sarcoma subtypes are sensitive to the stroma targeting antibody drug conjugate PYX-201 – Abstract #: 1854935 Read More »
Associations of the immunomodulatory molecule Siglec-15 gene and protein expression to immune gene signatures as a potential biomarker for Siglec-15 targeted therapy in non-small cell lung cancer – Abstract #: 219 By lsc-webmaster Associations of the immunomodulatory molecule Siglec-15 gene and protein expression to immune gene signatures as a potential biomarker for Siglec-15 targeted therapy in non-small cell lung cancer – Abstract #: 219 Read More »
Characterization and prevalence of the novel immunomodulatory protein Siglec-15 expression in tumor cells and macrophages across multiple solid tumor indications – Abstract # 521 By lsc-webmaster Characterization and prevalence of the novel immunomodulatory protein Siglec-15 expression in tumor cells and macrophages across multiple solid tumor indications – Abstract # 521 Read More »
PYX-106, a highly differentiated anti-Siglec-15 monoclonal antibody, reverses Siglec-15 mediated immune suppression and enhances cytotoxic activity in human lymphocytes – Abstract #: 567 By lsc-webmaster PYX-106, a highly differentiated anti-Siglec-15 monoclonal antibody, reverses Siglec-15 mediated immune suppression and enhances cytotoxic activity in human lymphocytes – Abstract #: 567 Read More »
PYX-201, EDB+FN is an attractive target in oncology: Insights from protein expression analysis of solid tumors – Abstract Number: 2908 By lsc-webmaster PYX-201, EDB+FN is an attractive target in oncology: Insights from protein expression analysis of solid tumors – Abstract Number: 2908 Read More »
PYX-201, a stroma-targeting ADC composed of an anti-EDB+FN antibody conjugated to Auristatin0101, demonstrates strong anti-tumor efficacy across multiple human cancer indications in pre-clinical PDX tumor models – Abstract Number: 742 By Dan PYX-201, a stroma-targeting ADC composed of an anti-EDB+FN antibody conjugated to Auristatin0101, demonstrates strong anti-tumor efficacy across multiple human cancer indications in pre-clinical PDX tumor models – Abstract Number: 742 Read More »
Extracellular proteolytic cleavage of peptide-linked antibody-drug conjugates promotes bystander killing of cancer cells – Abstract Number: 4837 By Dan Extracellular proteolytic cleavage of peptide-linked antibody-drug conjugates promotes bystander killing of cancer cells – Abstract Number: 4837 Read More »
PYX-106, Gene expression correlation of immune checkpoint molecules Siglec-15 and PD-L1 varies widely by cancer indication – Abstract Number: 1373 By walid PYX-106, Gene expression correlation of immune checkpoint molecules Siglec-15 and PD-L1 varies widely by cancer indication – Abstract Number: 1373 Read More »
